doi: 10.1016/j.celrep.2023.113643
Our licensed providers offer clinically supervised formulations, including BPC-157, MOT-S, Semaglutide, Tirzepatide, Retatrutide, Sermorelin, and more
E., Rasmussen, K., Njlstad, I., Refsum, H., Nilsen, D
E-Posters - RECOVERY, REHABILITATION AND OUTCOME 03.00 - RECOVERY, REHABILITATION AND OUTCOME - 03.03 - PROGNOSIS AND OUTCOME AFTER STROKE P2312 - ESOC25-2352 MAPPING THE MODIFIED RANKIN SCALE (MRS) INTO THE 5-LEVEL EQ-5D (EQ-5D-5L) IN ISCHEMIC STROKE PATIENTS Florentina Pinckaers 1 , Janneke Grutters 2 , Silvia Evers 3 , Hester Lingsma 4 , Jeroen Boogaarts 5 , Diederik Dippel 6 , Linda Jacobi-Postma 1 , Aad van der Lugt 7 , Charles Majoie 8 , Yvo Roos 9 , Robert van Oostenbrugge 10 , Wim Van Zwam 1 , Andrea Gabrio 11 1 Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, Maastricht, Netherlands, 2 Department for Health Evidence, Radboud UMC, Nijmegen, Netherlands, 3 Department of Health Services Research, Maastricht University, Centre of Economic Evaluation and Machine Learning, Trimbos Institute, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, Netherlands, 4 Department of Public Health, Erasmus MC University Medical Center, Rotterdam, Netherlands, 5 Department of Neurosurgery, Radboud UMC, Nijmegen, Netherlands, 6 Department of Neurology, Erasmus MC University Medical Center, Rotterdam, Netherlands, 7 Department of Radiology, Erasmus MC University Medical Center, Rotterdam, Netherlands, 8 Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, Netherlands, 9 Department of Neurology, Amsterdam UMC, Amsterdam, Netherlands, 10 Department of Neurology, Maastricht University Medical Centre+, Maastricht, Netherlands, 11 Department of Methodology and Statistics, Maastricht University, Maastricht, Netherlands Background and Aims: To translate the modified Rankin Score (mRS) at three months after ischemic stroke into EQ-5D-5L utility values, which may be used for the derivation of quality-adjusted life years for cost-effectiveness analyses
